Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients who need high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） therapy.~* 2. Patients who continued treatment for MMN without addition or increase at 30 days before informed consent.~* 3. Patients who MRC score increased 1 stage in greater than or equal to 2 muscles and not decreased relative other muscles to before at after in high-dose intravenous immunoglobulin therapy.~* 4. Patients with greater than or equal to twenty years old at informed consent.~Exclusion Criteria:~* 1. Patients treated with Plasmapheresis at 3 months before informed consent.~* 2. Patients treated with Rituximab or Natalizumab at 6 months before informed consent.~* 3. Patients treated with Interferon-beta at 6 months before informed consent.~* 4. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.~* 5. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.~* 6. Patients with history of shock or hypersensitivity for NPB-01.~* 7. Patients with IgA deficiency.~* 8. Patients with malignancy.~* 9. Patients with impaired liver function.~* 10. Patients with impaired renal function.~* 11. Patients with cerebro- or cardiovascular disorders.~* 12. Patients with high risk of thromboembolism.~* 13. Patients with hemolytic/hemorrhagic anemia.~* 14. Patients with decreased cardiac function.~* 15. Patients with decreased platelet.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- NPB-01 (Type: EXPERIMENTAL): Intravenous immunoglobulin

Based on this trial design, predict the completion outcome and termination type (if applicable).